<DOC>
	<DOCNO>NCT01974167</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety eldecalcitol monotherapy compare alfacalcidol monotherapy patient glucocorticoid-induced osteoporosis , use randomize , open-label , parallel-group , comparative design .</brief_summary>
	<brief_title>Eldecalcitol GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>( 1 ) Patients currently take plan take oral glucocorticoid medication 3 month longer thus require treatment per 'Guidelines management treatment glucocorticoidinduced osteoporosis Japanese Society Bone mineral Research ( 2004 ) , ' meet least one condition . No restriction impose underlying disease treat oral glucocorticoid medication . ( ) Have exist insufficiency fracture ( ii ) % YAM &lt; 80 ( iii ) Oral glucocorticoid daily dose &gt; = 5 mg prednisolone equivalent ( 2 ) Aged 20 85 year ( inclusive ) consent ( 3 ) Patients able walk without assistance ( 4 ) Provided consent participate study ( 1 ) BMD ( L14 THip ) T score &lt; 3.5 ( 2 ) Have 3 vertebral fracture L1 L4 . ( 3 ) Have 1 SQ grade 3 vertebral fracture , 3 SQ grade 2 vertebral fracture . ( 4 ) Have receive bisphosphonate preparation 2 week longer within 6 month start study treatment . ( 5 ) Have receive bisphosphonate preparation 2 year longer within 3 year start study treatment . ( 6 ) Have receive parathyroid hormone preparation start study treatment . ( 7 ) Have receive one dose antiRANKL ( receptor activator nuclear factorkappa B ligand ) antibody . ( 8 ) Have receive one dose antisclerostin antibody cathepsin K inhibitor . ( 9 ) Have receive investigational product ( include placebo ) within 16 week start study treatment present study . ( 10 ) Have receive following drug affect bone metabolism within 8 week start study treatment , exception calcium preparation : ( ) Bisphosphonates ( ii ) Active vitamin D preparation ( include topical use ) ( iii ) Selective estrogen receptor modulators ( SERMs ) ( iv ) Calcitonin preparation ( v ) Vitamin K2 preparation ( vi ) Ipriflavone preparation ( vii ) Reproductive hormone product ( except vaginal use vaginal tablet cream ) ( viii ) Other drug affect bone metabolism ( 11 ) Pregnant woman woman desire become pregnant ( 12 ) Have correct serum calcium &gt; = 10.4 mg/dL &lt; 8.0 mg/dL enrollment . ( 13 ) Have correct urinary calcium &gt; 0.4 mg/dL GF enrollment . ( 14 ) Have past current history urinary calculus . ( 15 ) Have eGFR &lt; 30 mL/min/1.73 m2 enrollment . ( 16 ) Have severe liver disease cirrhosis severe heart disease severe cardiac failure . ( 17 ) Have active malignancy receive treatment malignancy , include adjuvant therapy , within past 3 year . ( 18 ) Have history hypersensitivity eldecalcitol , alfacalcidol , vitamin D preparation . ( 19 ) Other person judge investigator ( subinvestigator ) inappropriate participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>glucocorticoid-induced osteoporosis</keyword>
</DOC>